• Antibody-mediated immunity is the key protective mechanism against RSV, guiding prophylaxis and vaccine design: palivizumab prophylaxis [1], protective neutralizing antibody thresholds [2], ultra-potent antibodies and neutralizing monoclonals [8], MAb efficacy comparisons [15], and humoral/mucosal protection in adults [20].

• RSV immune evasion shapes disease by interrupting interferon signaling and enabling persistence. Nonstructural protein 2 inhibits type I IFN signaling [14], IFN-pathway blockade [16], and latency/persistence despite T cell immunity [12].

• RSV pathogenesis and immunopathology link early infection to later wheeze and asthma, driven by cytokine imbalance and chemokine responses. Type 1/Type 2 imbalance in acute bronchiolitis [4], longitudinal asthma risk after infancy bronchiolitis [3], RSV-induced chemokines [11], and atopy-modulated nasal ILs [13].

• Vaccine design and preclinical modeling emphasize attenuation and immunity, using animal RSV models and G-protein-deficient constructs. Protollin-eRSV vaccine efficacy in mice [7], attenuated G-deficient RSV inducing protection [17], and vaccine-model considerations for hMPV [18].

• Epidemiology and surveillance analyses inform timing of RSV immune prophylaxis and track shifting disease dynamics. Outbreak timing analyses [6] and evolving RSV/Influenza epidemiology [10], guiding public health strategies.